Pancreatic Cancer Trial, Recruiting NCT07272187 Sponsor: Herlev Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07272187
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have one or more growths or lesions that can be treated using a procedure called EUS-RFA (a type of internal heat treatment guided by ultrasound)
  • You have a type of pancreatic tumour called an insulinoma that is 25mm or smaller, confirmed by a 72-hour fasting test, imaging scans, and a tissue sample showing slow-growing cells
  • You have a non-active pancreatic tumour between 10–20mm that is getting larger, confirmed by a tissue sample showing slow-growing cells, OR you have a larger pancreatic tumour and surgery is not a suitable option for you
  • You have a specific type of adrenal gland growth (called a unilateral APA) on the left side, confirmed by certain scans and a specialised blood sampling procedure (confirm with trial site)
  • You are an adult who is able to make your own decisions
  • You have read and signed a consent form agreeing to take part

Who may not be able to join:

  • You have serious or multiple severe health conditions that significantly affect your overall health and daily functioning (confirm with trial site)
  • You have a blood clotting problem that cannot be corrected, including certain abnormal blood test results related to clotting or low platelet counts
  • You are pregnant
  • You have a cancer that has spread to other parts of the body and your expected life expectancy is less than 3 years
  • You have a narrowing or change in the structure of your upper digestive tract (for example, if you have previously had part of your stomach removed) that would prevent a special camera scope from passing through

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bojan Kovacevic, MD, ph.d., Herlev and Gentofte Hospital, Capital Region of Denmark

Phone: 0045 3868 6312

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Herlev Hospital
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
31 December 2040

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Patient satisfaction; Clinical efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov